B. Perdiguero

Type de document

Articles (9)

Co-auteur

Date

Source

Mot-clé

vecteur (9) Cells (8) protéine (7) Expression (7) virus (6) Vaccinia (6) Mice (6) gène (5) Memory (5) Antigens (5) ADN (4) Deletion (4) Genes (4) Viruses (4) Immune response (4) DNA (4) Viruses (4) immunité (3) procès (3) Dendritic cells (3) Vaccination (3) T cells (3) Strategy (3) Proteins (3) Human beings (3) Macrophages (3) Interferon (3) Immunity (3) Cytokines (3) Receptors (3)

Documents écrit par B. Perdiguero (9) | parle de B. Perdiguero (0)

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
M. Giel-Moloney et al. (27 déc. 2019)
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
J. Delaloye et al. (2015)
Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C.
B. Perdiguero et al. (2013)
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
C.E. Gómez et al. (2012)
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.
L. Pattacini et al. (2012)
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
B. Perdiguero et al. (2012)
Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors.
E.D. Quakkelaar et al. (2011)
Improved NYVAC-based vaccine vectors.
K.V. Kibler et al. (2011)
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
J. Delaloye et al. (2009)